<code id='13AC19AD3D'></code><style id='13AC19AD3D'></style>
    • <acronym id='13AC19AD3D'></acronym>
      <center id='13AC19AD3D'><center id='13AC19AD3D'><tfoot id='13AC19AD3D'></tfoot></center><abbr id='13AC19AD3D'><dir id='13AC19AD3D'><tfoot id='13AC19AD3D'></tfoot><noframes id='13AC19AD3D'>

    • <optgroup id='13AC19AD3D'><strike id='13AC19AD3D'><sup id='13AC19AD3D'></sup></strike><code id='13AC19AD3D'></code></optgroup>
        1. <b id='13AC19AD3D'><label id='13AC19AD3D'><select id='13AC19AD3D'><dt id='13AC19AD3D'><span id='13AC19AD3D'></span></dt></select></label></b><u id='13AC19AD3D'></u>
          <i id='13AC19AD3D'><strike id='13AC19AD3D'><tt id='13AC19AD3D'><pre id='13AC19AD3D'></pre></tt></strike></i>

          knowledge

          knowledge

          author:knowledge    Page View:6
          Adobe

          Illumina, the leading maker of DNA sequencing machines, said Sunday that it would divest Grail, the developer of a multi-cancer screening test, which it bought over the objections of regulators in the U.S. and Europe in August 2021.

          Illumina said the decision to spin Grail off followed a Friday decision of the U.S. Fifth Circuit Court of Appeals, which held that the merger was anti-competitive. It said that it would divest Grail either by selling it to another company or listing it on capital markets, consistent with an order from the European Commission, and that it aims to finalize the terms of the deal by the end of the second quarter of 2024.

          advertisement

          The decision opens what should be the final chapter in one of the most disastrous attempted mergers in biotech history. Illumina, a storied name that had delivered investors strong returns over two decades, spun out Grail in 2016 in order to raise money to fund the company’s work. Then, it announced plans to re-acquire the firm for $7.1 billion in Sept. 2020.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          Alkermes shareholders re
          Alkermes shareholders re

          MarkLennihan/APAlkermesshareholdersvotedThursdaytore-electallofthedrugmaker’scurrentdirectors,ending

          read more
          Pioneering cancer drug will cost $475,000. Analysts call it a bargain
          Pioneering cancer drug will cost $475,000. Analysts call it a bargain

          VictorSeguraIbarraandRitaSerda,Ph.D.,NCI,NIHTheFoodandDrugAdministrationonWednesdayapprovedafuturist

          read more
          Novavax promises a turnaround & Lilly roils the obesity market
          Novavax promises a turnaround & Lilly roils the obesity market

          SammyKimballforSTATCanNovavaxfinallygetitright?What’sa“triple-G”drug?AndisNovoNordisklosingground?We

          read more

          Altering the blood type of lungs raises potential for universal organs for transplants

          DonorlungstreatedwithenzymestochangetheirbloodtypeareshowninanexvivolungperfusionmachineinthelabofMa